Comparison of two malaria multiplex immunoassays that enable quantification of malaria antigens.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
07 Jun 2022
Historique:
received: 17 11 2021
accepted: 25 05 2022
entrez: 7 6 2022
pubmed: 8 6 2022
medline: 10 6 2022
Statut: epublish

Résumé

Immunoassay platforms that simultaneously detect malaria antigens including histidine-rich protein 2 (HRP2)/HRP3 and Plasmodium lactate dehydrogenase (pLDH), are useful epidemiological tools for rapid diagnostic test evaluation. This study presents the comparative evaluation of two multiplex platforms in identifying Plasmodium falciparum with presence or absence of HRP2/HRP3 expression as being indicative of hrp2/hrp3 deletions and other Plasmodium species. Moreover, correlation between the malaria antigen measurements performed at these platforms is assessed after calibrating with either assay standards or international standards and the cross-reactivity among Plasmodium species is examined. A 77-member panel of specimens composed of the World Health Organization (WHO) international Plasmodium antigen standards, cultured parasites for P. falciparum and Plasmodium knowlesi, and clinical specimens with mono-infections for P. falciparum, Plasmodium vivax, and Plasmodium malariae was generated as both whole blood and dried blood spot (DBS) specimens. Assays for HRP2, P. falciparum-specific pLDH (PfLDH), P. vivax-specific pLDH (PvLDH), and all human Plasmodium species Pan malaria pLDH (PanLDH) on the Human Malaria Array Q-Plex and the xMAP platforms were evaluated with these panels. The xMAP showed a higher percent positive agreement for identification of hrp2-deleted P. falciparum and Plasmodium species in whole blood and DBS than the Q-Plex. For whole blood samples, there was a highly positive correlation between the two platforms for PfLDH (Pearson r = 0.9926) and PvLDH (r = 0. 9792), moderate positive correlation for HRP2 (r = 0.7432), and poor correlation for PanLDH (r = 0.6139). In Pearson correlation analysis between the two platforms on the DBS, the same assays were r = 0.9828, r = 0.7679, r = 0.6432, and r = 0.8957, respectively. The xMAP HRP2 assay appeared to cross-react with HRP3, while the Q-Plex did not. The Q-Plex PfLDH assay cross-reacted with P. malariae, while the xMAP did not. For both platforms, P. knowlesi was detected on the PvLDH assay. The WHO international standards allowed normalization across both platforms on their HRP2, PfLDH, and PvLDH assays in whole blood and DBS. Q-Plex and xMAP show good agreement for identification of P. falciparum mutants with hrp2/hrp3 deletions, and other Plasmodium species. Quantitative results from both platforms, normalized into international units for HRP2, PfLDH, and PvLDH, showed good agreement and should allow comparison and analysis of results generated by either platform.

Sections du résumé

BACKGROUND BACKGROUND
Immunoassay platforms that simultaneously detect malaria antigens including histidine-rich protein 2 (HRP2)/HRP3 and Plasmodium lactate dehydrogenase (pLDH), are useful epidemiological tools for rapid diagnostic test evaluation. This study presents the comparative evaluation of two multiplex platforms in identifying Plasmodium falciparum with presence or absence of HRP2/HRP3 expression as being indicative of hrp2/hrp3 deletions and other Plasmodium species. Moreover, correlation between the malaria antigen measurements performed at these platforms is assessed after calibrating with either assay standards or international standards and the cross-reactivity among Plasmodium species is examined.
METHODS METHODS
A 77-member panel of specimens composed of the World Health Organization (WHO) international Plasmodium antigen standards, cultured parasites for P. falciparum and Plasmodium knowlesi, and clinical specimens with mono-infections for P. falciparum, Plasmodium vivax, and Plasmodium malariae was generated as both whole blood and dried blood spot (DBS) specimens. Assays for HRP2, P. falciparum-specific pLDH (PfLDH), P. vivax-specific pLDH (PvLDH), and all human Plasmodium species Pan malaria pLDH (PanLDH) on the Human Malaria Array Q-Plex and the xMAP platforms were evaluated with these panels.
RESULTS RESULTS
The xMAP showed a higher percent positive agreement for identification of hrp2-deleted P. falciparum and Plasmodium species in whole blood and DBS than the Q-Plex. For whole blood samples, there was a highly positive correlation between the two platforms for PfLDH (Pearson r = 0.9926) and PvLDH (r = 0. 9792), moderate positive correlation for HRP2 (r = 0.7432), and poor correlation for PanLDH (r = 0.6139). In Pearson correlation analysis between the two platforms on the DBS, the same assays were r = 0.9828, r = 0.7679, r = 0.6432, and r = 0.8957, respectively. The xMAP HRP2 assay appeared to cross-react with HRP3, while the Q-Plex did not. The Q-Plex PfLDH assay cross-reacted with P. malariae, while the xMAP did not. For both platforms, P. knowlesi was detected on the PvLDH assay. The WHO international standards allowed normalization across both platforms on their HRP2, PfLDH, and PvLDH assays in whole blood and DBS.
CONCLUSIONS CONCLUSIONS
Q-Plex and xMAP show good agreement for identification of P. falciparum mutants with hrp2/hrp3 deletions, and other Plasmodium species. Quantitative results from both platforms, normalized into international units for HRP2, PfLDH, and PvLDH, showed good agreement and should allow comparison and analysis of results generated by either platform.

Identifiants

pubmed: 35672772
doi: 10.1186/s12936-022-04203-9
pii: 10.1186/s12936-022-04203-9
pmc: PMC9171962
doi:

Substances chimiques

Antigens, Protozoan 0
Protozoan Proteins 0
L-Lactate Dehydrogenase EC 1.1.1.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

176

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : INV1135840
Organisme : Spanish Ministry of Science and Innovation
ID : CEX2018-000806-S

Informations de copyright

© 2022. The Author(s).

Références

Am J Trop Med Hyg. 2017 Nov;97(5):1540-1550
pubmed: 28820709
J Clin Microbiol. 2014 Jun;52(6):2053-60
pubmed: 24696029
Emerg Infect Dis. 2008 Nov;14(11):1750-2
pubmed: 18976561
Immunobiology. 2006;211(10):797-805
pubmed: 17113917
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30404944
Sci Rep. 2022 May 4;12(1):7286
pubmed: 35508558
J Infect Dis. 2019 Jan 9;219(3):437-447
pubmed: 30202972
J Parasitol. 1979 Jun;65(3):418-20
pubmed: 383936
Am J Trop Med Hyg. 2021 Nov 15;106(1):275-282
pubmed: 34781260
Trends Parasitol. 2020 Feb;36(2):112-126
pubmed: 31848119
J Med Microbiol. 2013 Oct;62(Pt 10):1491-1505
pubmed: 24048274
Malar J. 2020 Sep 3;19(1):323
pubmed: 32883286
Science. 1976 Aug 20;193(4254):673-5
pubmed: 781840
Am J Trop Med Hyg. 2020 Jun;102(6):1366-1369
pubmed: 32189616
Malar J. 2018 Mar 17;17(1):118
pubmed: 29549888
Peptides. 2010 Apr;31(4):525-32
pubmed: 20093160
Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):479-83
pubmed: 9373661
Malar J. 2020 Jan 9;19(1):12
pubmed: 31918718
Parasit Vectors. 2019 Jun 10;12(1):293
pubmed: 31182154
J Clin Microbiol. 2017 Jul;55(7):2009-2017
pubmed: 28404673
Malar J. 2017 Aug 23;16(1):350
pubmed: 28835253
J Clin Microbiol. 2018 Jul 26;56(8):
pubmed: 29898998
Malar J. 2021 Apr 29;20(1):207
pubmed: 33926477
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):531-6
pubmed: 23267069
Malar J. 2014 Feb 18;13:60
pubmed: 24548805
Am J Trop Med Hyg. 2021 Apr 05;104(6):2139-2145
pubmed: 33819177
Clin Microbiol Rev. 2021 Jun 16;34(3):e0025020
pubmed: 34043447
Trans R Soc Trop Med Hyg. 2007 Apr;101(4):331-7
pubmed: 17212967
J Infect Dis. 2020 Mar 2;221(6):948-955
pubmed: 30852586
J Parasit Dis. 2021 Jun;45(2):479-489
pubmed: 34290484

Auteurs

Ihn Kyung Jang (IK)

Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA. ikjang@path.org.

Alfons Jiménez (A)

ISGlobal, Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Spain.
Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, 28029, Madrid, Spain.

Andrew Rashid (A)

Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.

Rebecca Barney (R)

Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.

Allison Golden (A)

Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.

Xavier C Ding (XC)

The Foundation for Innovative New Diagnostics, Campus Biotech, 9 Chemin des Mines, 1202, Geneva, Switzerland.

Gonzalo J Domingo (GJ)

Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.

Alfredo Mayor (A)

ISGlobal, Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Spain.
Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, 28029, Madrid, Spain.
Centro de Investigação Em Saúde de Manhiça Rua 12, Cambeve CP, 1929, Maputo, Mozambique.
Department of Physiologic Sciences, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH